Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2008 1
2011 2
2012 2
2013 2
2014 3
2016 5
2017 3
2018 2
2020 3
2021 2
2022 2
2023 6
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Jayne DRW, et al. N Engl J Med. 2021 Feb 18;384(7):599-609. doi: 10.1056/NEJMoa2023386. N Engl J Med. 2021. PMID: 33596356 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, Sahay M, Suzuki Y, Wong MG, Yarbrough J, Xia J, Pereira BJG; ENVISION Trial Investigators Group. Mathur M, et al. N Engl J Med. 2024 Jan 4;390(1):20-31. doi: 10.1056/NEJMoa2305635. Epub 2023 Nov 2. N Engl J Med. 2024. PMID: 37916620 Free PMC article. Clinical Trial.
Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease.
Caravaca-Fontán F, Díaz-Encarnación MM, Lucientes L, Cavero T, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juárez G, Rodríguez A, Pérez de José A, Rabasco C, Rodado R, Fernández L, Pérez Gómez V, Ávila AI, Bravo L, Lumbreras J, Allende N, Sanchez de la Nieta MD, Rodríguez E, Olea T, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, Cano-Megías M, González F, Shabaka A, López-Rubio ME, Fenollosa MÁ, Martín-Penagos L, Da Silva I, Alonso Titos J, Rodríguez de Córdoba S, Goicoechea de Jorge E, Praga M; Spanish Group for the Study of Glomerular Diseases GLOSEN. Caravaca-Fontán F, et al. Among authors: diaz encarnacion mm. Clin J Am Soc Nephrol. 2020 Sep 7;15(9):1287-1298. doi: 10.2215/CJN.15241219. Epub 2020 Aug 19. Clin J Am Soc Nephrol. 2020. PMID: 32816888 Free PMC article.
Clinical Profiles and Patterns of Kidney Disease Progression in C3 Glomerulopathy.
Caravaca-Fontán F, Cavero T, Díaz-Encarnación M, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juárez G, Rodríguez A, Pérez de José A, Rabasco C, Rodado R, Fernández L, Pérez-Gómez V, Ávila A, Bravo L, Espinosa N, Allende N, Sanchez de la Nieta MD, Rodríguez E, Rivas B, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, González F, Shabaka A, López-Rubio ME, Fenollosa MÁ, Martín-Penagos L, Da Silva I, Titos JA, Rodríguez de Córdoba S, Goicoechea de Jorge E, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN). Caravaca-Fontán F, et al. Among authors: diaz encarnacion m. Kidney360. 2023 May 1;4(5):659-672. doi: 10.34067/KID.0000000000000115. Epub 2023 Mar 30. Kidney360. 2023. PMID: 36996481 Free PMC article.
Clinical Uses of 1,25-dihydroxy-19-nor-vitamin D(2) (Paricalcitol).
Bover J, Dasilva I, Furlano M, Lloret MJ, Diaz-Encarnacion MM, Ballarin J, Cozzolino M. Bover J, et al. Among authors: diaz encarnacion mm. Curr Vasc Pharmacol. 2014 Mar;12(2):313-23. doi: 10.2174/15701611113119990028. Curr Vasc Pharmacol. 2014. PMID: 23713879 Review.
Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy.
Caravaca-Fontán F, Díaz-Encarnación M, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juárez G, Rodríguez A, Pérez de José A, Rabasco C, Rodado R, Fernández L, Pérez Gómez V, Ávila A, Bravo L, Espinosa N, Allende N, Sanchez de la Nieta MD, Rodríguez E, Olea T, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, Cano-Megías M, González F, Shabaka A, López-Rubio ME, Fenollosa MÁ, Martín-Penagos L, Da Silva I, Alonso Titos J, Rodríguez de Córdoba S, Goicoechea de Jorge E, Praga M. Caravaca-Fontán F, et al. Among authors: diaz encarnacion m. Nephrol Dial Transplant. 2022 Jun 23;37(7):1270-1280. doi: 10.1093/ndt/gfab075. Nephrol Dial Transplant. 2022. PMID: 33779754
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain.
Macía M, Díaz-Encarnación M, Solans-Laqué R, Mallol EP, Castells AG, Escribano C, de Arellano AR. Macía M, et al. Among authors: diaz encarnacion m. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb;24(2):227-235. doi: 10.1080/14737167.2023.2297790. Epub 2024 Jan 25. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 38126738
34 results